Based on these findings, different menin-MLL inhibitors have been tested in MLL-fused AML/ALL and beneficial therapeutic effects have been reported in several pre-clinical models [4,19,22,26]. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.